Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bendamustine
Drug ID BADD_D00230
Description Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Indications and Usage Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Marketing Status approved; investigational
ATC Code L01AA09
DrugBank ID DB06769
KEGG ID D07501
MeSH ID D000069461
PubChem ID 65628
TTD Drug ID D01CYA
NDC Product Code 68554-0050
UNII 9266D9P3PQ
Synonyms Bendamustine Hydrochloride | Hydrochloride, Bendamustine | Bendamustine | Bendamustin | Cytostasan | IMET 3393 | Ribomustin | Treanda | Zimet 3393
Chemical Information
Molecular Formula C16H21Cl2N3O2
CAS Registry Number 16506-27-7
SMILES CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Infusion site induration12.07.05.010; 08.02.05.0090.000381%Not Available
Infusion site pain12.07.05.002; 08.02.05.0140.002283%Not Available
Infusion site swelling12.07.05.003; 08.02.05.0020.000627%Not Available
Type III immune complex mediated reaction10.01.03.0230.000112%Not Available
Infusion site phlebitis08.02.05.003; 24.12.03.002; 12.07.05.0040.000627%Not Available
Infusion site reaction12.07.05.006; 08.02.05.0050.002339%Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000224%Not Available
Dysplasia08.03.04.0070.000112%Not Available
Angiopathy24.03.02.0070.000112%Not Available
Drug resistance08.06.01.0050.000112%Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Embolism24.01.01.0090.000112%
Haematotoxicity12.03.01.025; 01.05.01.0070.000246%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mantle cell lymphoma16.28.05.001; 01.15.05.0010.000246%Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Motor dysfunction17.01.02.031; 15.05.06.0060.000246%Not Available
White blood cell disorder01.02.05.0020.000112%Not Available
Anal cancer16.13.05.001; 07.21.05.0010.000112%Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Ill-defined disorder08.01.03.049--Not Available
Disease progression08.01.03.0380.002037%
Disease recurrence08.01.03.0500.000280%Not Available
Obstructive airways disorder22.03.01.0110.000112%Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.000168%Not Available
Hepatic lesion09.01.08.0050.000112%Not Available
Immunosuppression10.03.02.0010.000112%Not Available
The 10th Page    First    Pre   10 11 12    Next   Last    Total 12 Pages